All interferons (IFNs) signal through the JAK/STAT pathway, where engagement of the receptors induces sequential activation of Janus family (JAK and TYK) kinases and STATs, resulting in transcriptional activation of ISGs. In the absence of a stimulus, the cytoplasmic domain of the IFN receptor is bound by inactive JAK kinases. Upon IFN binding, these JAKs undergo phosphorylation and activation, which leads to phosphorylation of the IFN receptor and repositioning of STAT proteins. These STATs, now in proximity of the activated JAKs, are tyrosine-phosphorylated and released from the receptor. Activated STATs undergo homo-or heterodimerization and nuclear translocation. STAT1-2 heterodimers associate with IRF9 to form the active transcriptional complex ISGF3, while STAT homodimers are direct transcriptional activators. Typically, type I and III IFN signaling activates TYK2 and JAK1, resulting in STAT1-2 heterodimerization and ISGF3 formation, whereas type II IFN signaling activates JAK1 and JAK2 to induce STAT1 homodimerization. These components are present in basal state in the cell but remain latent until IFN receptor ligation.
Type I IFNs
Type I IFNs include IFN-α, β, ε, κ, and ω. The genetic loci of the various subtypes contain different regulatory elements, which likely contribute to differential control of spatio-temporal production. These subtypes also display differential binding affinities for their receptor, contributing to variable strengths of signaling. All type I IFNs signal through the ubiquitously expressed heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits, although signaling through IFNAR1 alone has recently been suggested (de Weerd et al., 2013) . Type I IFNs activate ISGF3, which binds to ISREs within the ISG promoters. IFN priming, a process wherein small amounts of IFN-β maintain high basal levels of STAT1/2 and IRF9, allows immune cells to rapidly respond to IFN signal. In specific cell types, other STAT family members (STAT3, 4, 5A/5B, and 6) can also be activated by type I IFN. Type I IFN is a major component of antimicrobial immune defense, as the induced ISG products function to restrict infection and modulate/enhance the adaptive immune response (Ivashkiv and Donlin, 2014) . Most cell types can respond to type I IFN.
Type II IFNs
Type II IFN refers to IFN-γ, which binds as a dimer to the IFNGR complex consisting of two IFNGR1 and two IFNGR2 subunits. Receptor activation induces JAK1 and JAK2 phosphorylation, which then phosphorylates the IFNGR1 chains to allow docking of STAT1. The receptor-recruited STAT1 pair is phosphorylated, homodimerizes, and translocates to the nucleus, where it binds GAS elements within the ISG promoters. IFN-γ does not typically induce ISGF3 to activate ISRE-driven genes. In contrast, STAT complexes induced by type I IFN can activate GAS elements. IFN-γ production is largely restricted to hematopoietic cells. IFNGR, on the other hand, is widely expressed; therefore, nearly all cell types are responsive to IFN-γ. IFN-γ signaling can induce gene products that prime the type I IFN response. Likewise, ISG products from type I IFN signaling can potentiate IFN-γ signaling. Overall, IFN-γ plays a pivotal role in regulating immune function, including polarizing the T cell response and activating myeloid cells, and bridging the innate and adaptive immune responses (Platanias, 2005) .
Type III IFNs
Type III IFNs include IFNl1, IFNl2, IFNl3 (first called IL-29, IL-28A, and IL-28B), and the recently described IFNl4. IFN-l binds to a heterodimeric receptor comprised of IFNLR1 (also known as IL-28Rα) and IL-10R2. While IL-10R2 is broadly distributed, the expression of IFNLR1, which is uniquely utilized by type III IFNs, is restricted to epithelial cells, subsets of myeloid cells, and certain neuronal cells. Thus, type III IFNs are thought to act predominantly at barrier surfaces, including mucosal linings and the blood-brain barrier (Sommereyns et al., 2008) . This receptor complex induces many of the same ISGs as type I IFN via ISGF3, hence it is assumed to utilize similar JAK/STAT components. However, recent studies suggest that JAK2, which is not involved in IFNAR signaling, mediates type III IFN signaling (Odendall and Kagan, 2015) . While JAK1 is a confirmed signaling component of type III IFN signaling, TYK2's role has not been conclusively demonstrated, even though its function has been assumed due to its association with IL-10R2. Type I and type III IFN signaling display different kinetics, and it has been shown that type III sustains signaling after type I peaks and subsides.
Complexity
Beyond the canonical pathways, IFNs operate on intricate levels of complexity that impart their pleiotropic effects. For example, STAT activity can be regulated by other posttranslational modifications, such as serine phosphorylation by IKKε and PKC (Decker and Kovarik, 2000) . Factors such as BRG1 interact with specific STATs to further modulate their activity. IFN responses are cell type and context specific, with overlapping, but often distinct, transcriptional output. Type I IFNs can enhance IFN-γ signaling by activating STAT1 homodimers that bind to GAS elements or antagonize IFN-γ signaling by downregulating IFN-γ receptor and other mechanisms (Kearney et al., 2013) . CRKL-STAT5 dimer induced by type I IFNs can also activate GAS-containing genes. Type III IFN stimulation can enhance responsiveness to IFN-γ (Liu et al., 2011) . Additional STATs also participate in IFN signaling. The accessibility, relative abundance, and permutation of the different STAT-containing complexes, each with varying affinity and preference for GAS sequences, determine the different biological outcomes and allow for fine-tuning of IFN response. Of the hundreds of known ISGs, some contain only ISRE or GAS elements, while others have both. Therefore, optimal induction of certain ISGs may require specific combinations of STAT-containing complexes. Unphosphorylated STATs can regulate the transcription of a subset of ISGs (Yang and Stark, 2008) , and the ability of STATs to both activate and repress gene transcription has recently been appreciated (Levy and Marié, 2012) . IFN signaling is negatively regulated by SOCS, USP18, and PIAS proteins. Of note, the JAK/STAT pathway is also utilized by other cytokine receptors, growth receptors, and G protein-coupled receptors, which likely cooperate and crosstalk with IFN pathways. Finally, IFN also activates PI3K and p38/ERK MAPK pathways, and the list of newly identified pathways and additional players is rapidly growing. These pathways regulate mRNA translation, autophagy, and other cellular functions, and together they form a complex network that confers the many facets of IFN response. ABBREVIATIONS IFN, interferon; JAK, Janus activated kinase; TYK2, tyrosine kinase 2; STAT, signal transducer and activator of transcription; ISG, interferon-stimulated gene; ISGF3, ISG factor 3; IRF9, interferon regulatory factor 9; IFNAR, IFN-α receptor; ISRE, IFN-stimulated response element; IFNGR, IFN-γ receptor; GAS, IFN-γ-activated DNA sequence; IKKε, inhibitor of NFκB kinase epsilon; PKC, protein kinase C; BRG1, Brahma-related gene-1; CRKL, v-CRK avian sarcoma virus CT10 oncogene homolog-like; SOCS, suppressors of cytokine signaling; USP18, ubiquitin specific peptidase 18; PIAS, protein inhibitor of activated STAT; PI3K, phosphatidylinositide 3 kinase; MAPK, mitogen activated protein kinase
